Real-World Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab in Italy
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:
• A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.
• Age ≥18 years at index date.
• With at least 12 months data availability prior to index date.
Locations
Other Locations
Switzerland
Novartis
RECRUITING
Basel
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: 2026-04-02
Estimated Completion Date: 2026-10-30
Participants
Target number of participants: 5995
Treatments
Inclisiran Cohort
Patients receiving inclisiran injection(s).
Evolocumab Cohort
Patients receiving evolocumab injection(s).
Alirocumab Cohort
Patients receiving alirocumab injection(s).
Pooled Anti-PCSK9-mAb Cohort
Patients receiving anti-PCSK9-mAbs either evolocumab or alirocumab.
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals